These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36645166)

  • 1. Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy.
    Pedersen S; Holmstroem RB; von Heymann A; Tolstrup LK; Madsen K; Petersen MA; Haslund CA; Ruhlmann CH; Schmidt H; Johansen C; Svane IM; Ellebaek E
    Acta Oncol; 2023 Jan; 62(1):62-69. PubMed ID: 36645166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.
    Rogiers A; Willemot L; McDonald L; Van Campenhout H; Berchem G; Jacobs C; Blockx N; Rorive A; Neyns B
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
    Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
    Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
    Egeler M; Lai-Kwon J; Tissier R; Fraterman I; Kuijpers A; Van Houdt W; Wilgenhof S; Rao A; Sandhu S; Lee R; Eriksson H; van Leeuwen M; de Ligt K; van Akkooi A; van de Poll-Franse L
    Eur J Cancer; 2024 Mar; 200():113601. PubMed ID: 38340383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel adjuvant options for cutaneous melanoma.
    Dimitriou F; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
    Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M
    Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
    Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in patients with fully resected BRAF
    Schadendorf D; Di Giacomo AM; Demidov L; Merelli B; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Hong A; Lewis K;
    Eur J Cancer; 2019 Dec; 123():155-161. PubMed ID: 31704549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma.
    Hemstock M; Amadi A; Kupas K; Roskell N; Kotapati S; Gooden K; Middleton MR; Schadendorf D
    Eur J Cancer; 2020 Jun; 132():176-186. PubMed ID: 32380428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
    Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
    Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience from 2 Tertiary Referral Centers.
    Morellá Fernández M; Balsalobre Yago J; Martínez García J; Peláez Gutiérrez M; López Muñoz A; Silvestre Ballesta AI; Sánchez Lafuente B; Martínez Martín I; Cerezuela Fuentes P
    Actas Dermosifiliogr; 2024 Sep; ():. PubMed ID: 39271008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
    Atkinson TM; Hay JL; Young Kim S; Schofield E; Postow MA; Momtaz P; Warner AB; Shoushtari AN; Callahan MK; Wolchok JD; Li Y; Chapman PB
    Oncologist; 2023 Apr; 28(4):351-357. PubMed ID: 36745014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
    Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J;
    Acta Oncol; 2013 Aug; 52(6):1086-93. PubMed ID: 23621752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
    Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC
    J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
    Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
    ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
    Bottomley A; Coens C; Mierzynska J; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Puig S; Ascierto PA; Larkin J; Lorigan PC; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C; Eggermont AMM;
    Lancet Oncol; 2021 May; 22(5):655-664. PubMed ID: 33857414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials.
    Bersanelli M; Petrelli F; Buti S; Stanganelli I
    Hum Vaccin Immunother; 2022 May; 18(3):1902723. PubMed ID: 33881961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.